Screening for chromosomal anomalies: combined test, cell-free DNA, diagnostic tests
- Routine care
A blood test and a scan can say whether the baby's chromosomes are likely to be normal. Only a needle test can say for sure, so the choice is the parents'.
See it in 3D: Body of uterus
What it is
Aneuploidy screening estimates the chance that a fetus has an extra or missing chromosome, mainly trisomy 21 (Down syndrome), trisomy 18 and trisomy 13. The combined test at 11 to 14 weeks uses the mother's age, the nuchal translucency on ultrasound and two blood markers (free beta-hCG and PAPP-A). The quadruple test in the second trimester uses four blood markers. Cell-free DNA testing, possible from about 10 weeks, reads fragments of placental DNA in the mother's blood and is the most sensitive screen. None of these is a diagnosis: a high-risk result is confirmed by chorionic villus sampling or amniocentesis, which read the chromosomes directly. Every step is offered with counselling and is voluntary.
What it looks for
- Trisomy 21 risk rises with the mother's age, but most babies with Down syndrome are born to younger mothers, because they have most babies; screening is offered to all ages.
- Combined test (11 to 14 weeks): in trisomy 21 the nuchal translucency is thick, free beta-hCG is high and PAPP-A is low; it finds most cases at a false-positive rate of about 5%.
- In trisomy 18 and 13, the hormone markers are typically all low.
- Cell-free DNA finds almost all trisomy 21 with very few false positives, but is less accurate for trisomy 13, sex chromosomes and small deletions.
- A thick nuchal translucency with normal chromosomes still raises the risk of heart defects and genetic syndromes: it calls for a detailed anatomy scan and fetal echocardiography.
How it is done
- Before any test: explain what is screened for, that it is optional and what a high-risk result would lead to.
- Confirm dating and number of fetuses with the 11 to 14 week scan; measure the nuchal translucency where trained staff are available.
- Offer the combined test, or cell-free DNA where it is available, as a first-line screen.
- Report the result as a risk (for example 1 in 50), not as positive or negative, and explain what it means for this couple.
- High risk: offer a diagnostic test (chorionic villus sampling from about 11 weeks, amniocentesis from 15 weeks), with genetic counselling.
- Structural anomaly on the scan: go straight to a diagnostic test with microarray, whatever the screening result.
- Low risk: continue routine care; the 18 to 24 week anatomy scan still looks for structural anomalies.
Screening versus diagnosis
| Feature | Combined or quadruple test | Cell-free DNA | Chorionic villus sampling or amniocentesis |
|---|---|---|---|
| What it measures | Scan and hormone markers | Fragments of placental DNA in maternal blood | The chromosomes of placental or fetal cells |
| Answer given | A risk figure | High or low risk (sometimes no result) | A diagnosis |
| When | 11 to 14 weeks; quadruple at 15 to 22 weeks | From about 10 weeks | Villus sampling from about 11 weeks; amniocentesis from 15 weeks |
| Miscarriage risk | None | None | Small, well under 1% |
| Main weakness | Misses some cases; more false positives | Placental DNA can differ from the fetus's | Invasive; villus sampling shares the placental mosaicism problem |
Common mistakes
- Calling a high-risk screen 'positive' and planning a termination on it: always confirm with a diagnostic test first.
- Skipping the nuchal measurement because cell-free DNA was done: the scan also finds major anomalies and thick nuchal folds with normal chromosomes.
- Ignoring a 'no result' from cell-free DNA: low fetal fraction is linked to aneuploidy and to maternal obesity, so offer a repeat or a diagnostic test.
- Wrong dates: the hormone markers depend on gestational age, so a dating error distorts the risk.
Next step / When to refer
- Offer screening to every pregnant woman with counselling, as the service offers it, and respect a decision not to be tested.
- Refer to fetal medicine and genetics for a high-risk screen, a nuchal translucency above the normal range or any structural anomaly.
- Use amniocentesis, not chorionic villus sampling, to confirm a high-risk cell-free DNA result when placental mosaicism is suspected.
- With a confirmed diagnosis: genetic counselling, a detailed scan and echocardiography, and an informed choice about continuing the pregnancy within the law.
Common traps
- A high-risk screen means the baby has Down syndrome: it means the chance is high enough to offer a diagnostic test, and most high-risk combined tests are false positives.
- Cell-free DNA is the baby's own DNA: it comes from the placenta, so a placenta with an abnormal cell line can give a false positive with a normal fetus.
- Only older mothers need screening: risk rises with age, but most affected babies are born to younger women, so screening is offered to all.
- Normal chromosomes close the case after a thick nuchal fold: the thick fold also flags heart defects and other syndromes, so a detailed scan and echocardiography follow.
Test yourself
Think of the answer, then tap the question to see it.
A combined test shows a thick nuchal translucency, high free beta-hCG and low PAPP-A. Which condition is suspected, and what is the next step?
Trisomy 21. Offer genetic counselling and a diagnostic test (chorionic villus sampling or amniocentesis); the screen alone is not a diagnosis.
Why can cell-free DNA be high risk when the fetus has normal chromosomes?
The DNA comes from the placenta. If the placenta carries an abnormal cell line that the fetus does not (confined placental mosaicism), the test reads the placenta, not the baby.
Chromosomes are normal after a nuchal translucency well above the normal range. Why is the work-up not finished?
A thick nuchal fold is also linked to congenital heart defects and other genetic syndromes, so a detailed anatomy scan and fetal echocardiography are needed.
Which diagnostic test is preferred to confirm a high-risk cell-free DNA result, and why?
Amniocentesis, because it samples fetal cells in the amniotic fluid; chorionic villus sampling tests the placenta, the same tissue that may have caused the false positive.
Elsewhere in DurgiPedia
- Prenatal diagnosis: ultrasound, serum screening, cell-free DNA, CVS, amniocentesis
- Meiosis and nondisjunction: where trisomies come from
- Preconception and prenatal genetics: screening, diagnosis and fetal therapy
- Chromosome abnormalities: number and structure
- First-trimester ultrasound: intrauterine pregnancy, dating and ectopic
- Genetic information: testing, confidentiality and relatives
Connections
See it in 3D1
The structures of Durgical's 3D anatomy where it is found.
← All of obstetrics and gynaecology
Educational content; it does not replace assessment by a doctor or your institution's protocols, and it contains no doses. For heavy bleeding, a severe headache or blurred vision, a seizure, fever, strong abdominal pain or fewer baby movements, go to an emergency department at once.
Sources: Prenatal Genetic Screening (StatPearls Publishing (NCBI Bookshelf), 2025); Amniocentesis (StatPearls Publishing (NCBI Bookshelf), 2023); Chorionic Villus Sampling (StatPearls Publishing (NCBI Bookshelf), 2025); Down Syndrome (StatPearls Publishing (NCBI Bookshelf), 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
